Tests diet advice and probiotics for pelvic pain in endometriosis and IBS
Tests diet guidance and Lactobacillus probiotics in women with endometriosis and irritable bowel syndrome.
Plain-language title generated from the registry record
Registry title: Impact of Dietary Guidance and Probiotics in the Treatment of Endometriosis and Irritable Bowel Syndrome in Women
Key facts
- Where
- Catanduva, BrazilSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 to 50 who have chronic pelvic pain from endometriosis together with irritable bowel syndrome. It tests diet guidance and probiotics.
- Age
- 18 to 50 years (the criteria text says 18 to 50; the registry header lists 15 to 50 years)
- Sex
- Women only
- Earlier treatment
- Cannot have used probiotics, antibiotics, antifungals, antihistamines, digestive medicines or treatments for constipation or diarrhea in the last 6 months. Cannot already eat healthy foods or follow a restrictive diet more than four days a week.
Main reasons for not taking part
- Endometriosis that needs surgery during the study
- Bowel diseases such as Crohn's disease, ulcerative colitis, microscopic colitis, celiac disease or lactose intolerance
- Pregnancy or breastfeeding
- Severe eating disorders
- Smoking in the last three years
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 15 and 50 years old?
Source: NCT07149519, who can take part
Where in Brazil
- Letícia Ferracini Lenharo HayashiCatanduva, BrazilContact: leticia hayashiTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Sao Paulo
- Trial code
- NCT07149519
- Record updated
- 2 September 2025
- Original description
Patients with endometriosis are 2 to 3 times more likely to develop Irritable Bowel Syndrome (IBS) than women without the condition. IBS presents symptoms similar to those of intestinal and deep EDT, leading to diagnostic errors and delays in identifying such comorbidities. Diets have shown positive effects on symptoms in women with both conditions, supporting the theory of a similar pathophysiology. The investigators goal is to examine how dietary practices and probiotic use affect chronic pelvic pain in patients with both comorbidities.Read full original descriptionShow less
Impact of Dietary Guidance and Probiotics in the Treatment of Chronic Pelvic Pain Secondary to Endometriosis and Irritable Bowel Syndrome in Women: A Randomized, Double-Blind Clinical Trial
Patients with endometriosis are 2 to 3 times more likely to develop Irritable Bowel Syndrome (IBS) than women without the condition. IBS presents symptoms similar to those of intestinal and deep EDT, leading to diagnostic errors and delays in identifying such comorbidities. Diets have shown positive effects on symptoms in women with both conditions, supporting the theory of a similar pathophysiology. The investigators goal is to examine how dietary practices and probiotic use affect chronic pelvic pain in patients with both comorbidities.
Inclusion: Women between 18 and 50 years of age who wish to participate in the clinical trial; Willingness to voluntarily participate in the study and accept randomization to any of the three treatment arms; Participating exclusively in this clinical trial during the study period; Signing the Informed Consent Form (ICF) approved by the Research Ethics Committee (CEP) and CONEP.
Exclusion: Endometriosis requiring surgical treatment during the study period; Inability to use oral medication; Chronic, severe, or uncompensated clinical conditions, such as: malnutrition (BMI <18); insulin-dependent diabetes (types 1 or 2); uncontrolled hypertension; lung disease such as asthma or other chronic obstructive pulmonary disease; hematologic and liver diseases; advanced-stage chronic kidney disease (grades 3, 4, and 5); metabolic disorders; and immunosuppression; Clinical conditions of the gastrointestinal tract that cause IBS-like symptoms, such as: inflammatory bowel disease (Chron's disease, ulcerative colitis), microscopic colitis, celiac disease, and lactose intolerance; Severe eating disorders, such as: bulimia, anorexia nervosa, and binge-eating disorder; Chronic use of any medication with potential interaction with probiotics, the intestinal microbiota, or the natural progression of the disease in the last 6 months (such as probiotics, antibiotics, antifungals, antihistamines, digestive medications, or treatments for constipation or diarrhea); History of alcohol or drug dependence; Inability to cooperate with investigators due to cognitive impairment or mental state; Patients who already consume healthy foods or are on a restrictive diet more than four days a week, which may affect the evaluation results; Patients whose stool protopastological examination is altered; Pregnancy or lactation; Smoking in the last three years.